GlassScriptPhysician profile
Christopher James Vaughan
NPI 1952574410
$1,023.82
in general payments reported to CMS, 2019-2025
18 companies · $373 in 2025
The $373 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $320 · 2020: $93.40 · 2021: $60.81 · 2023: $32.48 · 2024: $144 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $533 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $532.70 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $223.68 | 2024-2025 | Eterna |
| Glaxosmithkline, LLC. | $177.47 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $147.53 | 2019-2024 | Fasenra, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.31 | 2019-2020 | |
| Philips North America LLC | $64.64 | 2019-2021 | |
| Insmed, INC. | $59.80 | 2024-2025 | Brinsupri, Arikayce |
| Amgen INC. | $43.97 | 2025 | Tezspire |
| Merck Sharp & Dohme LLC | $41.84 | 2019-2024 | Zerbaxa |
| Astellas Pharma US INC | $28.50 | 2025 | Cresemba |
| Actelion Pharmaceuticals US, INC. | $26.52 | 2019 | |
| Genzyme Corporation | $24.26 | 2025 | |
| Avadel Cns Pharmaceuticals, LLC | $23.25 | 2025 | Lumryz |
| Novartis Pharmaceuticals Corporation | $19.64 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.43 | 2019 | |
| Lilly USA, LLC | $13.91 | 2025 | Zepbound |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $13.57 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.90 | 2020 | |
| Circassia INC. | $12.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Vaughan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.